readthroughSign in
Nov 10, 2026Financing

Alzamend Neuro restructures Series D deal with affiliate Ault Lending, cuts deal to $10 million

An amended agreement dated November 10, 2026 shrinks the preferred stock financing from $25 million to $10 million and splits it into two closings.

Alzamend Neuro, Inc. filed an amended Form 8-K on November 10, 2026 that restates terms of a securities purchase agreement with Ault Lending, LLC, which the filing identifies as an affiliate of the Company.1

The original agreement, dated July 31, 2026, had allowed the Purchaser to purchase up to $25 million in shares of the Series D Convertible Preferred Stock in one or more closings.1 On that date, the Company sold 7,500 Preferred Shares to the Purchaser, for a total cash purchase price of $7.5 million1 in what the filing calls the Initial Tranche Closing.

Under the newly signed Amended and Restated Securities Purchase Agreement, dated November 10, 2026, the Company shall sell to the Purchaser an aggregate of $10 million in Preferred Shares rather than $25 million, of which $7.5 million of Preferred Shares were sold to the Purchaser on the date of the Original Agreement in the Initial Tranche Closing.1 The remaining amount will close in a second tranche: the Company and the Purchaser agreed that the Purchaser shall purchase an additional $2.5 million in Preferred Shares at the second tranche closing.1

Each Preferred Share carries a stated value of $1,050 per share and does not accrue dividends.1 Conversion terms set the Conversion Price as the greater of $0.2668 (the Floor Price) and 80% of the lowest closing bid price of the Common Stock during the five trading days immediately prior to conversion, but not greater than $2.00 per share.1

The company also agreed to registration and governance deadlines. It committed to file a registration statement covering resale of shares issuable upon conversion of the Preferred Shares by November 17, 2026.1 Separately, it agreed to file a preliminary proxy statement no later than 15 days after the Execution Date and a definitive proxy statement within 45 days, seeking stockholder approval for issuance of Conversion Shares above the Nasdaq Limit of 19.99% of outstanding common stock.1 That special meeting shall occur no later than 75 days after the Execution Date.1

The amended and restated Certificate of Designations was filed with the Secretary of State of the State of Delaware on November 10, 2026.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.